KBLI 21012

Human Pharmaceutical Product Manufacturing

Industri Produk Farmasi untuk Manusia

🏭 Section C — Manufacturing

PMA status not yet verified for this KBLI 2025 code

❓PMA unverifiedHigh RiskDirect MatchOSS-verified · KBLI 2025

Kelompok ini mencakup pembuatan dan pengolahan obat-obatan, suplemen kesehatan/makanan, obat kuasi yang berbentuk jadi (sediaan) untuk manusia, misalnya dalam bentuk tablet, kapsul, salep, bubuk, larutan, larutan parenteral dan suspensi, obat kontrasepsi hormonal; produksi radiofarmaka; dan produksi farmasi bioteknologi.

Licensing Overview

Risk LevelTinggi

License TypeNIB + Izin

Foreign OwnershipNot verified — confirm in OSS

Processing7 working days

Authoritative BPS crosswalk

Official BPS 2020 → 2025 crosswalk ancestors: 21012

Source: the BPS 2020↔2025 conversion table, mechanically extracted and acceptance-gate verified. It shows which 2020 codes map to this 2025 code — provenance only, not a licensing claim: the regulatory regime of these predecessor codes has not been adjudicated as transferring.

PP 28/2025 licensing source

PP 28/2025 licensing-source codes (KBLI 2020 numbering): 21012

These codes identify the PP 28/2025 regulatory rows used as licensing sources for this page. They are not the official BPS 2020 → 2025 crosswalk and do not establish predecessor ancestry.

Sources & Verification

Each data layer below traces to a government source with its KBLI vintage — or is declared as a gap. Nothing in these layers is silently filled in.

Activity definition

BPS Peraturan 7/2025 + PP 28/2025VerifiedKBLI 2025

Title and scope as defined by the KBLI-2025 classification.

locator: OSS_RBA_2025_id_version_fff4053d

Risk & licensing

OSS RBA risk scope (ruang lingkup)VerifiedKBLI 2025

Risk category and licensing rows are KBLI-2025-native from the OSS Risk-Based Approach catalog.

locator: OSS_RBA_resiko_2025

Foreign ownership (PMA)

No adjudicated per-code official basisDeclared gap—

The canonical record declares a verification gap for the current ownership value. The instrument locator layer can identify a potentially applicable provision, but it does not verify this whole-code verdict; confirm it at oss.go.id before relying on it.

Dataset last updated 2026-08-15 · KBLI 2020 and KBLI 2025 reuse code numbers for different activities — cross-vintage rows are labeled, never merged silently.

Common Questions

Can foreigners operate a human pharmaceutical product manufacturing business in Indonesia?

Not yet verified. The canonical record carries a current PMA label for KBLI 21012 (Industri Produk Farmasi untuk Manusia), but no adjudicated per-code official basis and source vintage verify that whole-code verdict. Confirm the current treatment at oss.go.id before planning a PT PMA. (No adjudicated per-code official basis and vintage currently verify this verdict; confirm it at oss.go.id before relying on it.)

What license is required for KBLI 21012?

KBLI 21012 has a Tinggi risk classification. Required license: NIB + Izin. Processing time: 7.

What is KBLI 21012?

KBLI 21012 is the Indonesian business classification code for "Industri Produk Farmasi untuk Manusia" (Human Pharmaceutical Product Manufacturing). It falls under Section C of KBLI 2025, the Indonesian Standard Industrial Classification updated by BPS (Regulation 7/2025). The June 2026 KBLI 2025 transition window has closed; operators should verify the code's current OSS/NIB treatment before relying on it for licensing, reporting, or amendments.

How did KBLI 21012 change from KBLI 2020 to 2025?

According to the official BPS 2020 → 2025 crosswalk, KBLI 21012 has recorded KBLI 2020 ancestor(s) 21012. This is provenance only, not a licensing claim; no predecessor licensing regime is asserted to transfer. The June 2026 KBLI 2025 transition window has closed. If an NIB still relies on legacy KBLI 2020 mappings, treat the migration as overdue and verify/remediate the OSS record before new license applications, amendments, LKPM, import approvals, or investor/worker sponsorship.

Related Codes

21013Section C

Veterinary Pharmaceutical Product Manufacturing

Industri Produk Farmasi untuk Hewan

→

❓PMA unverifiedMedium-Low Risk

21011Section C

Human Pharmaceutical Raw Material Manufacturing

Industri Bahan Baku Farmasi untuk Manusia

→

❓PMA unverifiedHigh Risk

21014Section C

Veterinary Pharmaceutical Raw Material Manufacturing

Industri Bahan Baku Farmasi untuk Hewan

→

❓PMA unverifiedMedium-High Risk

21015Section C

Medical Diagnostics, Bandages & Health Support Devices

Industri Alat Diagnosis Medis, Perban, Kasa, dan Penunjang Kesehatan Lainnya

→